VTVT

Business Context and Reporting Period

vTv Therapeutics Inc. (VTVT) is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates for diabetes and chronic diseases. Its lead candidate, cadisegliatin, is a liver-selective glucokinase activator currently in Phase 3 trials for Type 1 diabetes. This Form 10-Q covers the quarterly period ended June 30, 2026.

Key Financial Metrics

Liquidity: As of June 30, 2026, the company held $86.6 million in cash and cash equivalents. Total liabilities were $8.96 million, primarily consisting of contract liabilities ($1.83 million) and accounts payable ($6.99 million).

Material Changes vs. Prior Period

• Revenue Surge: The company recorded $36.8 million in revenue for the six months ended June 30, 2026, compared to zero in the prior year. This was driven by a $20.0 million upfront fee from Newsoara Biopharma and the recognition of $16.9 million in deferred license revenue from G42 Investments following the transfer of IP rights.
• Profitability Shift: The company reported a net income of $11.1 million for the six-month period, a reversal from a net loss of $11.1 million in the same period in 2025. This turnaround was primarily due to the non-recurring revenue recognition mentioned above.
• Increased Operating Costs: Total operating expenses increased by $13.3 million (93.4%) year-over-year. R&D expenses rose by $10.8 million, largely due to increased clinical study and consulting costs for the cadisegliatin program. G&A expenses increased by $2.5 million, driven by higher payroll and share-based compensation.
• Cash Flow Improvement: Net cash used in operating activities decreased significantly to $2.3 million from $10.8 million in the prior year, reflecting the cash inflow from the Newsoara agreement.

Outlook, Risks, and Management Commentary

• Clinical Progress: The company expects to complete enrollment for the CATT1 Phase 3 trial for cadisegliatin in Type 1 diabetes in the third quarter of 2026. A Phase 2 trial in Type 2 diabetes in the Middle East (in partnership with G42) is expected to start screening in 2026.
• Future Funding: Management anticipates continuing to incur losses and negative cash flows from operations for the foreseeable future. Additional capital will be required to fund ongoing clinical trials and operations. The company is evaluating financing strategies, including equity investments and licensing.
• ATM Facility: The company has an At-The-Market (ATM) offering agreement with TD Cowen for up to $50.0 million. No shares were sold under this facility during the six months ended June 30, 2026.
• Risks: Key risks include the uncertainty of clinical trial outcomes, the need for substantial additional funding, and the potential dilution of shareholders from future equity offerings. The company has not generated any product revenue to date and relies on collaboration agreements.

Investor Verification Checklist

• Revenue Sustainability: Verify the non-recurring nature of the $36.8 million revenue, which stems from upfront license fees rather than product sales.
• Cash Burn Rate: Monitor the $2.3 million cash burn from operations for the six-month period against the $86.6 million cash balance to assess runway.
• Clinical Milestones: Track the completion of the CATT1 trial enrollment (expected Q3 2026) and the initiation of the G42 Phase 2 trial.
• Contract Liabilities: Review the remaining $1.83 million in contract liabilities to understand future revenue recognition obligations.
• Dilution Risk: Assess the impact of outstanding warrants (13.7 million shares) and options (1.5 million shares) on future share count.